EMA Withdrawn: Episalvan (Betulae cortex) — Amryt AG

View source ↗

Summary

Episalvan (Betulae cortex) has been withdrawn from the market in the EMA process.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wound Healing
• Wounds

Drugs mentioned

• Episalvan (Betulae cortex)

Snippet

Status: Withdrawn. Therapeutic area: Wounds and Injuries;Wound Healing. MAH: Amryt AG. Decision date: 07/06/2022